LB Pharmaceuticals Appoints Susan Kozauer As CMO
(RTTNews) - LB Pharmaceuticals Inc. (LBRX), a neuromedicines company, on Tuesday appointed Susan Kozauer as Chief Medical Officer.
Kozauer most recently served as Senior Vice President and Head of Clinical Development at Centessa Pharmaceuticals, a wholly owned subsidiary of Eli Lilly and Co. (LLY).
The company said Kozauer will lead the clinical development of LB-102 as the company prepares for topline results from its Phase 3 NOVA-2 trial in schizophrenia in the first half of 2027.
In the pre-market trading, LB Pharmaceuticals is 1.63% lesser at $44.11 on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.